How Many Doses in a 5-Amino-1MQ Vial? (Dosing Math)

A standard 50mg vial of 5-Amino-1MQ doesn't come pre-divided into doses. How many doses you extract depends entirely on the reconstitution volume you choose and the target dose per administration. Research protocols commonly use 0.5mg to 1.0mg per dose, which means a single vial yields 50 to 100 theoretical doses. But practical handling losses and measurement precision typically reduce that to 30–60 usable administrations. The difference between getting 30 doses versus 60 from the same vial comes down to reconstitution math, syringe accuracy, and whether you're accounting for dead volume in the vial.

Our team has guided hundreds of researchers through peptide reconstitution across multiple compound classes. The gap between theoretical yield and actual usable doses is where most calculation errors occur. And those errors compound across multi-week protocols.

How many doses are in a 5-Amino-1MQ vial?

A 50mg vial of 5-Amino-1MQ reconstituted with 5mL bacteriostatic water yields a 10mg/mL solution. Meaning each 0.1mL (10-unit mark on an insulin syringe) contains 1mg. At a research dose of 0.5mg per administration, that vial provides 100 theoretical doses, though practical yield is closer to 90–95 doses after accounting for measurement variance and vial residue. At 1mg per dose, the same vial yields 50 doses.

What Determines How Many Doses a Vial Yields

The number of doses you extract from a 5-Amino-1MQ vial is determined by three variables: the total peptide mass in the vial (typically 50mg), the volume of bacteriostatic water used for reconstitution, and the target dose per administration. A 50mg vial reconstituted with 2.5mL yields a 20mg/mL concentration; the same vial reconstituted with 10mL yields 5mg/mL. Higher concentrations mean smaller injection volumes per dose but require more precise measurement.

Research protocols typically use 5-Amino-1MQ doses ranging from 0.5mg to 1.5mg per administration, with 1mg being the most common benchmark. At 1mg per dose with a 10mg/mL reconstitution (5mL total volume), you draw 0.1mL per administration. That's the 10-unit mark on a standard U-100 insulin syringe. A 50mg vial at this concentration provides exactly 50 draws before depletion. If your protocol calls for 0.5mg doses, you halve the draw volume to 0.05mL (5 units), doubling the vial's yield to 100 theoretical doses. Drawing 5 units consistently on a 0.3mL insulin syringe requires deliberate technique, and variance of even 1–2 units per draw compounds across dozens of administrations.

Reconstitution Volume and Concentration Calculations

Reconstitution volume dictates concentration, which dictates per-dose draw volume. The formula is straightforward: concentration (mg/mL) = total peptide mass (mg) ÷ reconstitution volume (mL). A 50mg vial reconstituted with 5mL bacteriostatic water yields 10mg/mL. That same vial reconstituted with 2mL yields 25mg/mL. A higher concentration that reduces injection volume but increases the precision required for accurate dosing.

If your protocol requires 1mg per dose and you reconstitute 50mg in 10mL (yielding 5mg/mL), each dose requires drawing 0.2mL. That's the 20-unit mark on a U-100 syringe. At 0.2mL per dose, a 10mL vial provides 50 administrations. If instead you reconstitute the same 50mg in 5mL (yielding 10mg/mL), each 1mg dose requires only 0.1mL, and the vial still provides 50 administrations. But the smaller draw volume reduces measurement error. The choice between 5mL and 10mL reconstitution doesn't change total doses when the target dose remains constant; it changes draw volume per dose and the margin for syringe measurement error.

Syringe Precision and Practical Yield Loss

Theoretical doses assume perfect measurement and zero waste. Neither occurs in practice. A 50mg vial reconstituted to 5mL theoretically provides 50 doses at 1mg per dose, but actual yield drops to 45–48 doses for three reasons: vial residue (0.1–0.2mL remains after the final draw), measurement variance (±1–2 units per draw), and air bubbles. These losses are predictable. Plan for 90–95% of the theoretical yield.

Syringe type determines measurement precision. Standard U-100 insulin syringes are graduated in 1-unit increments, where each unit represents 0.01mL. Drawing 10 units (0.1mL) from a 10mg/mL solution delivers 1mg. But variance of ±1 unit means actual dose ranges from 0.9mg to 1.1mg. That 10% variance is acceptable in most protocols. For doses below 0.5mg, variance increases to ±20% unless you switch to a low-dead-space 0.3mL syringe with half-unit graduations. Researchers aiming for sub-0.5mg doses achieve better consistency by increasing reconstitution volume to lower the concentration.

What If: 5-Amino-1MQ Dosing Scenarios

What If I Want 0.5mg Doses — How Should I Reconstitute the Vial?

Reconstitute the 50mg vial with 10mL bacteriostatic water to yield a 5mg/mL solution. Each 0.1mL draw (10 units on a U-100 syringe) then delivers 0.5mg. A volume large enough for consistent measurement. At this concentration, the vial provides 100 theoretical doses, reduced to 90–95 practical doses after accounting for residue and variance. Attempting to achieve 0.5mg doses from a 10mg/mL solution requires drawing only 5 units per dose, which introduces significant measurement error.

What If I'm Using a 30mg Vial Instead of 50mg?

A 30mg vial reconstituted with 3mL bacteriostatic water yields the same 10mg/mL concentration as a 50mg vial reconstituted with 5mL. At 1mg per dose, the 30mg vial provides 30 theoretical doses (28–29 practical doses). The math scales proportionally. Divide total peptide mass by your target dose to determine theoretical yield, then reduce by 5–10% for practical handling losses.

What If I Miss a Dose Mid-Protocol — Should I Double Up the Next One?

No. Resume your regular dosing schedule with the standard dose. 5-Amino-1MQ's mechanism involves sustained NNMT inhibition, which doesn't require daily dosing to maintain efficacy. Missing a single administration does not justify dose-doubling, which could introduce variability in plasma concentration curves. If you've missed more than three consecutive doses, consider whether restarting the titration phase is appropriate for your research design.

The Unvarnished Truth About 5-Amino-1MQ Vial Yields

Here's the honest answer: most researchers overestimate how many usable doses they'll extract from a vial because they calculate theoretical yield without accounting for real-world handling losses. A 50mg vial does not provide 100 administrations at 0.5mg per dose. It provides 90 to 95 if you're meticulous about technique, and fewer if you're not. The single biggest yield loss comes from vial residue: after your final draw, 0.1–0.2mL of solution remains adhered to the vial walls and rubber stopper, representing 1–2mg of peptide you'll never extract. Add measurement variance (±1 unit per draw across 50 draws compounds to ±50 units total error), and practical yield drops another 2–5 doses below the theoretical maximum. This isn't a flaw in the peptide or the vial. It's inherent to liquid handling at sub-millilitre volumes. Plan your reconstitution math assuming 90% yield, not 100%, and you'll avoid running short mid-protocol.

Most researchers new to peptide reconstitution fail because they choose concentration based on theoretical math instead of their actual syringe precision. If you're drawing 5 units per dose with a standard insulin syringe, your measurement error is ±20%. That level of variance makes dose consistency nearly impossible across a 12-week protocol. The solution isn't a more expensive syringe; it's a lower concentration achieved by increasing reconstitution volume. Draw 10 units instead of 5, accept the slightly larger injection volume, and your variance drops to ±10%. That difference. Halving your measurement error. Matters more than saving 0.05mL of injection volume per administration.

What This Means for Multi-Week Research Protocols

A 50mg vial of 5-Amino-1MQ supports research timelines ranging from 25 to 50 days depending on dosing frequency and target dose. At 1mg per day, a single vial provides approximately 45–48 days of uninterrupted administration when reconstituted to 10mg/mL. At 0.5mg per day, the same vial extends to 90–95 days. These timelines assume proper storage (refrigerated at 2–8°C after reconstitution, protected from light) and adherence to the 28-day use window for bacteriostatic water-reconstituted peptides.

Reconstituted 5-Amino-1MQ remains stable for up to four weeks when stored correctly, but peptide degradation accelerates after that window. If your protocol spans 12 weeks at 1mg per day, you'll need three 50mg vials: vial one covers days 1–45, vial two covers days 46–90, and vial three covers days 91–105. Stagger your vial orders so fresh powder arrives before you deplete your current supply. Most researchers set a standing order timed to their dosing schedule rather than ordering reactively.

Protocols requiring doses below 0.5mg or above 1.5mg introduce additional calculation complexity. At 0.25mg per dose, a 50mg vial theoretically yields 200 doses. But measurement precision at that level requires either ultra-low-volume syringes or reconstitution to very low concentrations. At 2mg per dose, a 50mg vial provides only 25 doses, meaning weekly administration across a 6-month study requires 10+ vials.

FAQ

How many doses are in a 50mg vial of 5-Amino-1MQ?

A 50mg vial yields 30–60 practical doses depending on reconstitution volume and target dose per administration. At the most common research dose of 1mg per administration with 5mL reconstitution volume (10mg/mL concentration), expect 47–49 usable doses after accounting for vial residue and measurement variance. At 0.5mg per dose, the same vial provides 90–95 practical doses.

What is the best reconstitution volume for 5-Amino-1MQ?

Most researchers use 5mL bacteriostatic water for a 50mg vial, yielding a 10mg/mL solution where 0.1mL (10 units on an insulin syringe) delivers a standard 1mg dose. This concentration balances ease of measurement with minimal injection volume. For doses below 0.5mg, increase reconstitution to 10mL to improve draw accuracy; for doses above 1.5mg, reduce to 2.5–3mL to keep injection volumes manageable.

How long does reconstituted 5-Amino-1MQ remain stable?

Reconstituted 5-Amino-1MQ maintains stability for up to 28 days when refrigerated at 2–8°C and protected from light. Bacteriostatic water contains benzyl alcohol as a preservative, which prevents bacterial growth for approximately four weeks. Beyond that window, both sterility and peptide integrity decline even under refrigeration. Any temperature excursion above 8°C accelerates degradation, so transport reconstituted vials in an insulated cooler if moving between lab spaces.

Can I use the same vial for multiple research subjects?

Yes, provided you follow aseptic technique for every draw: wipe the rubber stopper with 70% isopropyl alcohol before inserting the needle, use a fresh sterile syringe for each draw, and never reinsert a used needle into the vial. Each penetration of the stopper introduces potential contamination risk, so limiting draws to the minimum necessary reduces microbial introduction. Label the vial with the reconstitution date and discard after 28 days regardless of remaining volume.

What happens if I accidentally draw too much solution per dose?

If you've drawn excess solution but haven't yet administered it, you cannot return it to the vial. Doing so introduces contamination. Discard the excess dose and draw fresh solution for the next administration. For future draws, improve accuracy by drawing slightly past your target volume, then expelling the excess back into the vial before removing the needle. This technique ('overfill and correct') minimises air bubbles and improves dose consistency. Mark your syringe at the exact unit line corresponding to your target dose before inserting it into the vial.

How do I calculate doses if my vial contains 30mg instead of 50mg?

Use the formula: practical doses = (total peptide mass in mg × 0.9) ÷ target dose per administration in mg. The 0.9 multiplier accounts for 10% handling loss. A 30mg vial at 1mg per dose yields approximately 27 practical doses; at 0.5mg per dose, approximately 54 doses. Reconstitute 30mg vials with 3mL bacteriostatic water to maintain the standard 10mg/mL concentration, ensuring your per-dose draw volumes remain consistent with 50mg vial protocols.

Does syringe type affect how many doses I can extract?

Yes. Syringe dead volume and graduation precision both impact practical yield. Standard U-100 insulin syringes have approximately 0.01–0.02mL dead volume (solution trapped in the needle hub after injection), which reduces effective dose by 1–2% per administration. Low-dead-space syringes reduce this loss to under 0.005mL. For protocols requiring dozens of administrations, switching to low-dead-space syringes recovers 2–3 additional doses per vial. Graduation precision matters more: syringes with half-unit markings improve measurement accuracy for doses below 0.5mg.

Can I reconstitute 5-Amino-1MQ with sterile water instead of bacteriostatic water?

Sterile water lacks the benzyl alcohol preservative present in bacteriostatic water, meaning reconstituted peptide must be used within 24–48 hours to prevent bacterial growth. For single-use applications or same-day multi-dose protocols, sterile water is acceptable. But for vials intended to last multiple weeks, bacteriostatic water is essential. Never substitute bacteriostatic saline (0.9% NaCl with benzyl alcohol) for bacteriostatic water with peptides unless the manufacturer explicitly states compatibility. Salt content can alter peptide solubility and stability.

What is the most common dosing error researchers make with 5-Amino-1MQ?

The most frequent error is choosing reconstitution volume based on theoretical math rather than actual syringe precision. Researchers calculate that 2.5mL reconstitution yields the highest concentration and smallest injection volume, then struggle with measurement consistency because they're drawing 2–5 units per dose on a syringe graduated in 1-unit increments. That introduces 20–40% variance per dose. The solution is counterintuitive: increase reconstitution volume to 10mL, accept the slightly larger injection volume, and draw 10–20 units per dose instead. Halving measurement error and improving protocol consistency.

How should I dispose of a depleted 5-Amino-1MQ vial?

Treat depleted peptide vials as biohazardous sharps waste. Place the empty vial (with needle still attached if drawing directly) into a rigid sharps container, seal when full, and dispose through your institution's biohazard waste stream. Do not discard peptide vials in regular trash or recycling. Most research institutions have specific protocols for chemical and biological waste that include peptides. Rinse the vial with 70% ethanol before disposal if required by your facility's waste management guidelines.

Does 5-Amino-1MQ require refrigeration before reconstitution?

Lyophilised (freeze-dried) 5-Amino-1MQ is stable at room temperature (15–25°C) for short-term storage but should be kept at −20°C for long-term stability beyond 6 months. Once reconstituted with bacteriostatic water, refrigeration at 2–8°C is mandatory. Peptide degradation accelerates rapidly at room temperature after hydration. Never freeze reconstituted peptide solutions; ice crystal formation denatures the protein structure irreversibly. If transporting reconstituted vials between locations, use an insulated cooler with ice packs to maintain the 2–8°C range throughout transit.

Can I mix 5-Amino-1MQ with other peptides in the same vial?

No. Never combine different peptides in a single vial unless you have explicit stability and compatibility data from the manufacturer. Even peptides with similar storage requirements can interact unpredictably when mixed, altering solubility, degradation rates, or biological activity. If your protocol requires co-administration of multiple compounds, reconstitute each peptide in separate vials and draw them into separate syringes, then administer sequentially at different injection sites. The only exception is pre-mixed peptide blends specifically formulated and tested by the manufacturer for combined use.